{"id":"NCT00232739","sponsor":"Cordis Corporation","briefTitle":"Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions","officialTitle":"A Multicenter, Non-Randomized Study of the 2.25mm Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-09","primaryCompletion":"2004-11","completion":"2009-08","firstPosted":"2005-10-05","resultsPosted":"2010-02-08","lastUpdate":"2010-03-16"},"enrollment":100,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Coronary Artery Disease"],"interventions":[{"type":"DEVICE","name":"CYPHER Sirolimus-eluting Coronary Stent","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"The main objective of this study is to assess the safety and effectiveness of the sirolimus-eluting Bx VELOCITYTM stent in reducing in-lesion restenosis in patients with de novo native coronary artery lesions.","primaryOutcome":{"measure":"Percentage of Participants Who Experienced In-lesion Restenosis as Measured by Quantitative Coronary Angiography (QCA) at 6 Months Post-procedure","timeFrame":"From post-procedure to 6 months","effectByArm":[{"arm":"2.25mm Sirolimus-eluting Bx VELOCITYâ„¢ Balloon-exp Stent","deltaMin":16.9,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["17126649"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":91},"commonTop":["Target Vessel Failure","Target Vessel Revascularization (All)","Myocardial Infarction (Q wave or Non-Q wave)","Target Lesion Revascularization","Target Vessel Revascularization not involving Target Lesion"]}}